Michael Dunn: From ISTH 2026 to Better Outcomes for the Bleeding Disorders Community
Michael Dunn, Vice President – Head of Rare Disease Portfolio at Genentech, shared on LinkedIn:
”Reflections from a phenomenal ISTH Congress in Paris!
Attending this year’s International Society of Thrombosis and Haemostasis (ISTH) congress was a powerful reminder that transforming care for the bleeding disorders community requires much more than just laboratory breakthroughs.
It demands a holistic, long-term dedication to reshaping how individuals affected by bleeding disorders experience daily life.
Progress is driven by a deeply connected network of patients, clinicians, advocacy groups, and industry partners working together to dismantle existing barriers and build a healthcare framework that stands the test of time.
My three highlights were:
- Collaborative Momentum: The energy throughout the congress halls proved that real innovation happens when we work together and listen to the lived experiences of families and healthcare providers.
- Leadership in Action: I am incredibly grateful to the leadership across Roche and Genentech who were on the ground with us, engaging directly with the community to share our vision and commitment to advancing science for generations to come. Thank you Teresa Harris Graham Padraic Ward and Charlotte Owens, MD, FACOG for your engagement and demonstration of our long-term commitment to individuals with bleeding disorders.
- An Enduring Promise: At Roche and Genentech, we are not focused on short-term milestones. We are committed to remaining in this space to deliver even better medicines that are accessible to the individuals who rely on us.
- A special shout out to our congress leads: Omar Khalil and Bianca Heidersdorf, and to key partners across Roche and Genentech who came together to demonstrate our long-term commitment Mauricio Bordonaba Darine Ghanem, Kelly Fathers, Jose Vicente Cardona, Romain Chafaie, Gina Noh, Juliana Lagrasta Biondo and Tony Lin and many more. I am incredibly grateful and proud of the several colleagues who showed up to listen, learn and take the next steps forward together. I’m returning home fully energized for the journey ahead.
Here for Generations, Here for Life.”
Stay updated with Hemostasis Today.
-
Oct 18, 2026, 08:02Neda Ashayeri: Global Perspectives on Hemophilia and Rare Bleeding Disorders in Abu Dhabi
-
Oct 18, 2026, 07:55Anu Thomas: A Stepwise Laboratory Approach to Positive IAT and Pretransfusion Compatibility
-
Oct 18, 2026, 07:49Matthew Hazell: Molecular Matching and the Future of Transfusion Practice
-
Oct 18, 2026, 07:05Behnood Bikdeli: Vasculearn Network Highlights Expert Perspectives on PE Risk Stratification and Advanced Therapies
-
Oct 18, 2026, 06:27Gregory Makris: NEJM Study Supports Earlier Catheter-Directed Intervention in Intermediate-High–Risk PE
-
Oct 18, 2026, 06:26Danny Hsu: BLOOD 2026 Return to Aotearoa
-
Oct 18, 2026, 02:43Priya Sriskandarajah: Diagnosis and Management of PV and JAK2-Unmutated Erythrocytosis
-
Oct 18, 2026, 02:41C. Michael Gibson: A Meta-Analysis of DOACs and DAPT After Left Atrial Appendage Closure
-
Oct 18, 2026, 02:27What Hematologists Should Remember About the Person Behind the Platelet Count – ASH